Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy

20021,931 citationsJournal Article

Authors

Deborah Grady · University of California, San Francisco

David Herrington

Abstract

Lower rates of CHD events among women in the hormone group in the final years of HERS did not persist during additional years of follow-up. After 6.8 years, hormone therapy did not reduce risk of cardiovascular events in women with CHD. Postmenopausal hormone therapy should not be used to reduce risk for CHD events in women with CHD.

Topics & Keywords

Menopause: Health Impacts and Treatments Estrogen and related hormone effects Sex and Gender in Healthcare

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA

Volume 288, Issue 1, pp. 49-49

DOI: 10.1001/jama.288.1.49

Field-Weighted Citation Impact: 125.43